UNSPSC 51181578: Dapagliflozin

Dapagliflozin is a medication used to treat type 2 diabetes and, with certain restrictions, type 1 diabetes. It is also used to treat adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure

UNSPSC 51181578 Dapagliflozin is a Commodity code encompassing pharmaceutical products used in state and local government health and wellness programs, though recent state and local procurement activity under this code shows no substantive opportunities. The single relevant posting in the recent opportunities block—Seminole County's June 2026 IFB for Naloxone and Safe Drug Deactivation Systems—addresses opioid crisis response and harm reduction rather than dapagliflozin specifically, suggesting either mislabeling or minimal current demand for this particular pharmaceutical in state and local procurement channels. State and local health departments, county health systems, fire departments, and EMS services are typical buyers when pharmaceutical codes activate; however, the source does not document active competitive solicitations for dapagliflozin itself, and the recent opportunities block reflects broader pharmaceutical, medical supply, and health services procurement rather than diabetes medication procurement specifically.

No state and local government entities have issued RFPs, RFQs, ITBs, or IFBs specifically for dapagliflozin in the source materials. The code shows little current pursuit-relevant activity. Vendors monitoring this code should track health department medication acquisition and county EMS pharmaceutical supply contracts more broadly, as those will signal when jurisdictions are actively sourcing diabetes medications; today's sourcing pattern does not support pursuit here.